Vinge has represented the international private equity firm Cinven and Danish life science investment company Novo Holdings in their sale of Envirotainer Holding AB to EQT X Fund and Mubadala Investment Company, at an enterprise value of about EUR 2.8 billion. Vinge was supported by Clifford Chance.

Envirotainer develops, manufactures and leases active temperature-controlled containers, used primarily for air freighting biopharma products. The company was founded in 1985 in Stockholm and today its R&D, production and headquarters are based in the Stockholm region. With a global presence with about 375 employees in 20 countries and a fleet of about 6,500 containers, Envirotainer is the market leader in air transportation of temperature sensitive pharmaceuticals.

The Vinge team primarily consisted of Christina Kokko, Samra Baytar, Vilhelm Rondahl, Gustav Persson and Ida Redander (M&A), Victoria Gunnerek, Trine Osen Bergqvist and Ebba Thoms (EU, Competition & Regulatory), Linn Adelwald (Banking & finance), Isabell Nielsen and Sam Fakhraie Ardekani (Corporate Commercial), Sara Strandberg, Veronika Garemark, Emil Lindvall and Tove Tullberg (Employment & Corporate Crime), Kristoffer Larson (Real Estate), Axel Lennartsson and Rebecca Målquist (IP), Nicklas Thorgerzon (GDPR), Martin Boström (IT), Johan Cederblad and Lina Österberg (Permits & Environment), Viktoria Owetz Leyva, Christoffer Widström and Sara Dahlros Sköld (VDR).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024